- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Epidiolex
Recent news which mentions Epidiolex
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
December 09, 2024
From Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
August 23, 2024
From Benzinga
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
August 02, 2024
Tickers
NEWS
From Benzinga
$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
July 23, 2024
From Benzinga
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
July 11, 2024
From Benzinga
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 18, 2024
From Benzinga
Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users
March 12, 2024
From Benzinga
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
November 30, 2023
Tickers
JAZZ
From Benzinga
Unlocking Smiles: New Study Reveals Oral CBD As Safe & Effective Opioid Alternative For Dental Pain
November 16, 2023
Tickers
CL
From Benzinga
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
November 16, 2023
Tickers
JAZZ
From Benzinga
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
November 03, 2023
From Benzinga
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
August 09, 2023
Tickers
JAZZ
From Benzinga
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
July 10, 2023
From Benzinga
UK Mom's Concern As No Doctor Will Prescribe Cannabis For Her Daughter's 300 Daily Seizures
June 02, 2023
Tickers
CBD
From Benzinga
FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
May 30, 2023
Tickers
JAZZ
From Benzinga
From Benzinga
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
February 02, 2023
Tickers
JAZZ
From Benzinga
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
January 05, 2023
From Benzinga
From Benzinga
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
November 10, 2022
Tickers
JAZZ
From Benzinga
From Benzinga
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
September 29, 2022
Tickers
JAZZ
From Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
June 09, 2022
Tickers
JAZZ
From Benzinga
From Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
May 27, 2022
From Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
March 03, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.